Dated: June 28, 2006.

Michelle Shortt,

Director, Regulations Development Group, Office of Strategic Operations and Regulatory Affairs.

[FR Doc. E6–10587 Filed 7–6–06; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Administration for Developmental Disabilities

Award To: Oregon Health & Science University, Child Development & Rehabilitation Center.

Purpose: To supplement a grant award for support of ''Making It Real: Participatory Action Research (PAR) for University Centers for Excellence in Developmental Disabilities (UCEDDs)''.

Amount of Award: $65,000 for one year.

Project Period: 7/1/2006—6/30/2007.

Justification for Exception to Competition: After consulting with relevant, informed sources, including individuals with developmental disabilities and their families, the Administration for Developmental Disabilities (ADD) determined that it was beneficial to continue funding the Oregon Health & Science University, Child Development & Rehabilitation Center project to strengthen and expand the inclusion of people with developmental disabilities and their family members in participatory action research projects at University Centers for Excellence in Developmental Disabilities (UCEDDs).

The Oregon Institute on Disability & Development, the Oregon Health and Science University, Child Development and Rehabilitation Center will receive a sole source program expansion supplemental grant for ''Making It Real: Participatory Action Research (PAR) for UCEDDs,'' a training initiative on the critical and emerging needs of individuals with developmental disabilities and their families. Through the project, a tool kit is being created that will include tested educational modules on participatory action research. Through the creation of the toolkit, every UCEDD will be able to access resources that will enhance and increase PAR and support initiatives that are most meaningful to people with developmental disabilities and their families. It will also be available to individuals with developmental disabilities, family members, advocacy groups, and other interested organizations. By continuing funding of this project, additional resources will be developed, including materials in Spanish. In addition, the expansion supplement will allow for more time and resources to enhance training and dissemination efforts.

The Administration for Children and Families intends to supplement the current grant by $65,000. The grantee will continue to provide a 25 percent match.

FOR FURTHER INFORMATION CONTACT: Jennifer G. Johnson, Ed.D., Program Specialist, Administration on Developmental Disabilities, 200 Independence Avenue, SW., Room 405–D, Washington, DC 20201. Telephone: 202/690–5982 (v); 202/205–8037 (f). E-mail: *jennifer.johnson@acf.hhs.gov.*

Dated: June 21, 2006.

Patricia A. Morrissey,

Commissioner, Administration for Developmental Disabilities.

[FR Doc. E6–10578 Filed 7–6–06; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 1990D–0428]

Human-Labeled Drugs Distributed and Used in Animal Medicine; Withdrawal of Compliance Policy Guide

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; withdrawal.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal of a compliance policy guide (CPG) that was issued on March 19, 1991.

DATES: July 7, 2006.

FOR FURTHER INFORMATION CONTACT: Diane D. Jeang, Division of Compliance Policy (HFC–230), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 240–632–6833.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of July 30, 1992 (57 FR 33729), FDA announced the availability of a revised CPG 7125.35 entitled ''Human-Labeled Drugs Distributed and Used in Animal Medicine.'' The CPG is being withdrawn because it is obsolete. This CPG explained how FDA would exercise its enforcement discretion with respect to the distribution and use of human-labeled drug products for use in animals.

The Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) was signed into law on October 22, 1994. AMDUCA allows veterinarians to prescribe extralabel uses of approved animal drugs and approved human drugs for animals under certain conditions. An extralabel use must be by or on the order of a licensed veterinarian within the context of a veterinarian-client-patient relationship and must be in conformance with the implementing regulations published in part 530 (21 CFR part 530). A list of drugs specifically prohibited from extralabel use in animals is in § 530.41.

With the enactment of AMDUCA and the issuance of implementing regulations, FDA is withdrawing CPG 7125.35 because it is obsolete. On September 24, 1998, a CPG section 615.100 entitled ''Extralabel Use of New Animal Drugs in Food-Producing Animals (CPG 7125.06)'' was withdrawn for the same reason (63 FR 51074).

Dated: June 20, 2006.

Margaret O'K. Glavin,

Associate Commissioner for Regulatory Affairs.

[FR Doc. E6–10672 Filed 7–6–06; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2006D–0214]

Streptomycin Residues in Cattle Tissues; Withdrawal of Compliance Policy Guide

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; withdrawal.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal of the compliance policy guide (CPG) entitled ''Sec. 616.100 Streptomycin Residues in Cattle Tissues (CPG 7125.22).'' This CPG is obsolete.

DATES: The withdrawal is effective July 7, 2006.

FOR FURTHER INFORMATION CONTACT: Diane D. Jeang, Division ofCompliance Policy (HFC–230), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 240–632–6833.

SUPPLEMENTARY INFORMATION: FDA issued the CGP entitled ''Sec. 616.100 Streptomycin Residues in Cattle Tissues (CPG 7125.22)'' on October 1, 1980. The CPG was issued because there were no published tolerances for residues of streptomycin in cattle tissue and the available data supported an action level of 2 part per million (ppm) streptomycin/dihydrostreptomycin

residues in cattle kidney tissue. The U.S. Department of Agriculture, Food Safety Quality Service (now known as the Food Safety Inspection Service) agreed to report any detectable residues in other edible tissue and to report to FDA only those cattle kidney tissue reports where the streptomycin residue was 2 ppm or more.

Since issuing this CPG, FDA has established tolerances for dihydrostreptomycin (59 FR 41976, August 16, 1994) and streptomycin (58 FR 47210, September 8, 1993). Tolerances are established for residues of dihydrostreptomycin in uncooked, edible tissues of cattle and swine of 2.0 ppm in kidney and 0.5 ppm in other tissues, and 0.125 ppm in milk. (See 21 CFR 556.200.) Tolerances are established for residues of streptomycin in uncooked, edible tissues of chickens, swine, and calves of 2.0 ppm in kidney, and 0.5 ppm in other tissues. (See 21 CFR 556.610.)

FDA is withdrawing CPG 7125.22, in its entirety, to eliminate obsolete compliance policy.

Dated: June 20, 2006.

Margaret O'K. Glavin,

Associate Commissioner for Regulatory Affairs.

[FR Doc. E6–10671 Filed 7–6–06; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information collection requests under review by the Office of Management and Budget (OMB), in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. chapter 35). To request a copy of the clearance requests submitted to OMB for review, call the HRSA Reports Clearance Office on (301) 443–1129.

The following request has been submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995:

Proposed Project: The Health Education Assistance Loan (HEAL) Program: Forms (OMB No. 0915–0034 Extension)

The HEAL program provides federally insured loans to assure the availability of funds for loans to eligible students to pay for their education costs. In order to administer and monitor the HEAL program, the following forms are utilized: The Application for Contract of Federal Loan Insurance form (used by lenders to make application to the HEAL insurance program and formerly entitled Lenders Application for Contract of Federal Loan Insurance form); the Borrower's Deferment Request form (used by borrowers to request deferments on HEAL loans and used by lenders to determine borrower's eligibility for deferment); the Borrower Loan Status update electronic submission (submitted monthly by lenders to the Secretary on the status of each loan); and the Loan Purchase/Consolidation electronic submission (submitted by lenders to the Secretary to report sales, and purchases of HEAL loans).

The estimates of burden for the forms are as follows:

Collection activity	Number of respondents	Responses per respondent	Total responses	Hours per response	Total burden hours
Application for Contract of Federal Loan Insurance	17	1	17	8 min	3
Borrower's Deferment Request:					
Borrowers	436	1	436	10 min	73
Employers	261	1.669	436	5 min	36
Borrower Loan Status Update	8	18	144	10 min	24
Loan Purchase/Consolidation	17	248	4,216	4 min	281
Total	739		5,249		417

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: John Kraemer, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: June 29, 2006.

Cheryl R. Dammons,

Director, Division of Policy Review and Coordination.

[FR Doc. E6–10591 Filed 7–6–06; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Advisory Committee to the Director, National Institutes of Health (NIH).

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated witht he grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal property.

Name of Committee: Advisory Committee to the Director, NIH.

Date: August 17, 2006.

Time: 2 p.m. to 3 p.m.

Place: National Institutes of Health, Building 31, 31 Center Drive, Room 5B64, Bethesda, MD 20892.

Agenda: To review and evaluate grant applications (Telephone Conference Call).

Contact Person: Shelly Pollard, ACD Coordinator, National Institutes of Health, 9000 Rockville Pike, Building 31, Room 5B64, Bethesda, MD 20892, (301) 496–0959, *pollards@mail.nih.gov.*